Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Tables)

v3.21.1
Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2021
Stockholders' Equity Note [Abstract]  
Schedule of warrants
    Shares
Underlying
Warrants
    Weighted
Average
Exercise
Price
    Weighted
Average
Remaining
Contractual
Life (years)
    Aggregate
Intrinsic Value
 
Outstanding and exercisable at December 31, 2020     17,058,051     $ 1.86       5.78     $ -  
Granted     6,340,020       2.10                  
Exercised     (14,267,250 )     1.24               387   
Outstanding at March 31, 2021     9,130,821     $ 3.00       3.95     $ -  
Schedule of stock option activity
    Shares Underlying Options     Weighted Average Exercise Price     Weighted Average Remaining Contractual Life (years)     Aggregate Intrinsic Value  
Outstanding at December 31, 2020     5,029,119     $ 3.00       7.96     $ -  
Granted     1,109,500       1.78                  
Forfeited     (143,905 )     3.73                  
Outstanding at March 31, 2021     5,994,714     $ 2.76       8.26     $ -  
Schedule of option pricing model using weighted average assumptions
    Three Months Ended
March 31,
 
    2021     2020  
Expected term, in years     5.7       5.8  
Expected volatility     106.90 %     79.59 %
Risk-free interest rate     0.71 %     1.49 %
Dividend yield     -       -  
Grant date fair value   $ 1.43     $ 0.95  
Schedule of restricted stock unit awards activity
    Number of Shares     Weighted Average Grant Date Fair Value  
Nonvested at December 31, 2020     337,925     $ 3.10  
Granted     426,000       1.78  
Vested     (65,915 )     2.75  
Nonvested at March 31, 2021     698,010     $ 2.33  
Schedule of stock-based compensation
    Three Months ended
March 31,
 
    2021     2020  
Research and development   $ 134     $ 223  
Sales and marketing     117       128  
General and administrative     668       453  
Total   $ 919     $ 804